 These compounds have good oral bioavailability and properties that promote them to be a good candidate for a subtype inhibitor of MMP-13 based diseases and future development.Pyrimidine dicarboxamides are highly selective MMP-13 inhibitors.In the S1’ pocket of MMP-13 is an S1’ side pocket that is unique to the matrix metalloproteiase.